|

LY4066434. Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Eli Lilly and Company1

Indications

  • Pancreatic Ductal Adenocarcinoma1
  • Metastatic Solid Tumor1
  • Advanced Solid Tumor1
  • Colorectal Cancer1
  • Lung Cancer1

Birmingham, Alabama1 trial

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

University of Alabama at Birmingham

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.